The research group participated in ARPA-H's GLIDE program to find new treatments for diseases related to the lymphatic system, from rare congenital diseases to common chronic diseases. The program focuses on developing therapies to help reduce symptoms, while restoring and regenerating the dysfunctional lymphatic system.
Professor Arthur Christopoulos, Head of Pharmacy and Pharmaceutical Sciences, said this study "represents a new boundary of medicine".
Monash University's research program aims to develop a new generation oral medication to restore the natural pumping and transportation function of the lymphatic system, based on a highly selective and flexiblely adjustable molecular mechanism.
This method was pioneered by a research group at the Monash Institute of Pharmaceutical Sciences (MIPS), allowing the development of safer, more selective and more effective drugs that work in the right place, at the right time and in the right type of tissue, while limiting side effects in other parts of the body.
The study received a maximum funding of 22.4 million AUD (approximately 420 billion VND) from the Agency for Advanced Research Projects in Health (ARPA-H).